SCHEMBL18247

SCHEMBL18247

Nc1nc2[nH]cnc2c(=O)n1Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PNP P00491 4/20 0.59
KDM4E B2RXH2 2/20 0.49
ADORA3 P0DMS8 1/20 0.48
ADORA2B P29275 1/20 0.48
PDE4A P27815 5/20 0.47
PDE4B Q07343 5/20 0.47
PDE4C Q08493 5/20 0.47
PDE4D Q08499 5/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 3/20 0.45
MEN1 O00255 1/20 0.45
RGS12 O14924 1/20 0.45
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1980958 0.99 PNP (0.57) PNPKDM4EADORA3ADORA2BPDE4A
SCHEMBL22631569 0.90 PNP (0.49) PNPKDM4EADORA3ADORA2BPDE4A
Hydrochloric Acid SCHEMBL17186508 0.88 PNP (0.47) PNPKDM4EADORA3ADORA2BPDE4A
SCHEMBL1262618 0.88 PNP (0.45) PNPKDM4EADORA3ADORA2BPDE4A
SCHEMBL3308556 0.88 PNP (0.45) PNPKDM4EADORA3ADORA2BPDE4A
SCHEMBL4966454 0.88 PNP (0.45) PNPKDM4EADORA3ADORA2BPDE4A
SCHEMBL1533545 0.87 MPO (0.48) PNPPDE4APDE4BPDE4CPDE4D
SCHEMBL6268523 0.87 ADORA2B (0.53) PNPKDM4EADORA3ADORA2BKMT2A
SCHEMBL3310264 0.87 PNP (0.44) PNPKDM4EADORA3ADORA2BPDE4A
SCHEMBL3021036 0.87 PNP (0.44) PNPKDM4EADORA3ADORA2BPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5536 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746918-A1 METHODS OF PREPARING SURFACE MODIFIED VIRAL CAPSIDS Borea Therapeutics S.r.l. (IT) 2026-05-27 EP claimed
US-20260130982-A1 METHODS FOR ASSEMBLING PROTEIN-CONJUGATED NANOCARRIER VACCINES UNIV NORTHWESTERN (US) 2026-05-14 US claimed
WO-2026085618-A1 METHOD OF IMMOBILIZING CAPTURE PROBES TO SOLID PHASES FOR TARGET SUBSTANCE DETECTION YYZ PHARMATECH INC. (CA) 2026-04-30 WO claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-20260103737-A1 ENZYMATIC METHODS TO GENERATE HIGH YIELDS OF SEQUENCE SPECIFIC RNA OLIGONUCLEOTIDES WITH EXTREME PRECISION UNIV MASSACHUSETTS (US) 2026-04-16 US claimed
EP-4716533-A2 FLUORESCENT INDICATORS FOR METAL ION DETECTION AS SUBSTRATES FOR A SELF-LABELING ENZYME Ion Biosciences (US) 2026-04-01 EP claimed
EP-3336099-B1 METHOD FOR SELECTIVELY BINDING CELLS TO A BINDING PARTNER AND DEVICE COMPRISING CELLS KARLSRUHER INST TECHNOLOGIE (DE) 2026-03-04 EP claimed
US-12560608-B2 Detection of molecular associations CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2026-02-24 US claimed
EP-4688872-A1 CLICK-TO-INSTALL GENOME EDITING The General Hospital Corporation (US) 2026-02-11 EP claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
EP-1054890-A1 OLIGODEOXYRIBONUCLEOTIDES COMPRISING O6-BENZYLGUANINE AND THEIR USE THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) 2000-11-29 EP claimed
WO-1999041269-A1 OLIGODEOXYRIBONUCLEOTIDES COMPRISING O6-BENZYLGUANINE AND THEIR USE THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1999-08-19 WO claimed
EP-0922458-A1 Potentiation of temozolomide by an ATase inhibitor CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 1999-06-16 EP claimed
WO-1999025386-A1 delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE CASE WESTERN RESERVE UNIVERSITY (US) 1999-05-27 WO claimed
EP-0910246-A1 USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS THE PENN STATE RESEARCH FOUNDATION (US) 1999-04-28 EP claimed
WO-1997035477-A1 USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS THE PENN STATE RESEARCH FOUNDATION (US) 1997-10-02 WO claimed
EP-0775142-A1 SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) 1997-05-28 EP claimed
WO-1996004281-A1 SUBSTITUTED O6-BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1996-02-15 WO claimed
EP-0679086-A1 POTENTIATION OF TEMOZOLOMIDE IN HUMAN TUMOUR CELLS CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) 1995-11-02 EP claimed
WO-1994015615-A1 POTENTIATION OF TEMOZOLOMIDE IN HUMAN TUMOUR CELLS CANCER RESEARCH CAMPAIGN TECHNOLOGY, LTD. (GB) 1994-07-21 WO claimed